Bayer Sees Flat 2026 Profits Amid Roundup Settlement Efforts
Bayer AG forecast profits and sales to be little changed in 2026 as the German agriculture and health company grapples with generic competition for its blockbuster blood thinner and continued uncertainty over its efforts to contain a pesticide litigation in the US.
📰 Original Source
Read full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.